Genomenon
genomenon.com
Actively hiring
Bioinformatics
Precision Medicine
Genomics & Genetic Testing
As featured in
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$31.5M
7 rounds on record
Latest round
$6M
Venture round · Jul 2026 · 3 mo ago
Team
60
US Form 5500 (plan participants) · Dec 2025 · -23% in a year
Hiring now
1
open roles
Grants
$2.1M
3 grants · CORDIS
Backers
1
IrishAngels
The money's age
Fresh money
3 months since the last round · hiring slowed
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 30
New executive Brian Groark, Executive Officer · SEC Form D
Jul 15
Raised a round Venture round $6M · SEC Form D
Mar 10
Partnership Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis · marketwatch.com
2025
Team shrank to 60 was 78 · US Form 5500 (plan participants)
May 9, 2024
Acquisition Genomenon Acquires Variant Database, Team From Jackson Laboratory · genomeweb.com
May 1, 2024
Raised a round Venture round $5.5M · SEC Form D
Jun 28, 2023
Acquisition Genomenon Acquires Boston Genetics To Accelerate Curation of Human Genome · technologynetworks.com
Mar 9, 2022
Raised a round Series B $20M
Sep 21, 2021
Won a grant $1.7M · CORDIS
May 15, 2020
Took on debt financing $2.9M · SEC Form D
May 1, 2019
Won a grant $153k · CORDIS
Feb 13, 2017
Won a grant $224k · CORDIS
2014
Founded
Tractionpublic signals, read monthly
Web presence
top 0.08%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2026 | $6M | — | SEC Form D |
| Venture round | May 2024 | $5.5M | — | SEC Form D |
| Series B | Mar 2022 | $20M | — | medindia.net |
| Grant | Sep 2021 | $1.7M | — | CORDIS |
| Debt Financing | May 2020 | $2.9M | — | SEC Form D |
| Grant | May 2019 | $153k | — | CORDIS |
| Grant | Feb 2017 | $224k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Genomenon, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Mark KielExecutive Officer, DirectorSEC Form D
Michael KleinExecutive Officer, DirectorSEC Form D
Steve SchwartzExecutive OfficerSEC Form D
Sam GlobusExecutive OfficerSEC Form D
Sean KearneyExecutive OfficerSEC Form D
Brian GroarkExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
IrishAngels Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Unlock the potential of a Whole Genome Sequencing Test with Inocras. Transforming diagnosis and treatment for cancer and rare diseases.
Accelerating Precision Medicine. Clinical research products bundled with cutting-edge bioinformatics to accelerate precision cancer therapy.
Enabling Precision Medicine Biomedical data analysis is transforming medicine. Through the growth of genomic, imaging, sensor, and other…
Velsera is a leading provider of omics analytics solutions, powering precision medicine and enhancing the healthcare and life sciences…
Ovation is a genomic data company committed to unlocking the potential of human genomic data to accelerate precision medicine.
SeqOne is the all-in-one genomic analysis platform trusted by 140+ labs worldwide. Speed up insights, ensure clinical-grade accuracy, and…
News
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis
Genomenon today announced a strategic sponsorship from Amicus Therapeutics to accelerate awareness, diagnosis, and research for Fabry disease. Through this collaboration, Genomenon produced literature-derived real-world evidence by applying fit-for-purpos
Read more
Report
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis
Read more
Report
Next-generation AI brings powerful new insight into genomic data
Genomenon Genomic Graph (G3) knowledgebase combines patient and biological data from nearly all published scientific and medical studies, including demographics, clinical characteristic...
Read more
Report
Perspective: The Future of Precision Medicine Depends on Collaboration Across the Healthcare Landscape
Success in this field demands investment in infrastructure, expanded education for healthcare providers, and improved access to genetic services.
Read more
Report
GenomOncology Inks Deal to Offer Access to Genomenon Genomic Data
Genomenon's Mastermind platform includes thousands of curated genes and a catalog of gene-disease relationships.
Read more
Report
Genomenon Mastermind ACMG Secondary Findings Variants Update
Genomenon has added curated variants for American College of Medical Genetics and Genomics (ACMG) secondary findings genes to its Mastermind Professional Edition software platform. The update enables labs to interpret these variants in patient testing dat
Read more
Report
High-Growth Companies Honored at 2024 FastTrack Awards, Celebrating Regional Economic Vitality
With Chris Sing, Principal at Rehmann and Ann Arbor SPARK Board member, serving as the emcee, the event brought together the region's most innovative businesses for a night of recognition and celebration. As the spotlight shone on these dynamic companies,
Read more
Report
Genomenon Acquires Variant Database, Team From Jackson Laboratory
The Ann Arbor, Michigan-based company acquired the Clinical Knowledgebase (CKB) along with 14 JAX employees and several contractors.
Read more
Report
Trendspotting: What's Coming for Diagnostics in 2024
Explore Diagnostics World's news highlights to stay updated on the regulatory and commercialization landscape of diagnostics. Explore articles now!
Read more
Report
Trendspotting: What's Coming for Clinical Trials and Research in 2024
Discover the Latest News in Clinical Research, Clinical Trials, Medical Informatics, & More. Clinical Research News Online Provides Daily Insights, News, & Analysis for the Clinical Research Industry.
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Genomenon over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
1
Stack modernity
64/100
Languages
SQL
Developer tools
Microsoft Excel
Sign in to see how your skills match this stack
Sign In
People
Mark Kiel
Executive Officer, Director
Michael Klein
Executive Officer, Director
Steve Schwartz
Executive Officer
Sam Globus
Executive Officer
Sean Kearney
Executive Officer
Brian Groark
Executive Officer
David Gregorka
Director
Patricia Glaza
Director
Charles Moret
Director
Michael Gross
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
48/100
Stable
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~3 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Sales
100% ▲
Offices
Where the company hires and what each office is for
Cities
15
Hiring now
0
Countries
4
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Ann Arbor
United States
HQ
GENOMENON
206 E. Huron St. Suite 114 Ann Arbor, MI 48104
New York
United States
Regional office
New York City, NY
San Francisco
United States
Regional office
San Francisco, CA
Los Angeles
United States
Regional office
Anaheim, CA
Brussels
Belgium
Regional office
Belgium
Frankfurt am Main
Germany
Regional office
Germany
Sacramento
United States
Regional office
Sacramento, CA
San Jose
United States
Regional office
San Jose, CA
Fort Wayne
United States
Regional office
Fort Wayne, IN
Boston
United States
Regional office
Boston, MA
Cincinnati
United States
Regional office
Cincinnati, OH
Columbus
United States
Regional office
Columbus, OH
Sarajevo
Bosnia and Herzegovina
Regional office
Sarajevo, Bosnia and Herzegovina
Tuzla
Bosnia and Herzegovina
Regional office
Tuzla, Bosnia and Herzegovina
Davis
United States
Regional office
Davis, CA
Financials
Total raised
$36.5M
Latest round
Venture - Series Unknown
Funding rounds
7